A new therapeutic approach in the medical treatment of cushing's syndrome: Glucocorticoid receptor blockade with mifepristone

Endocrine Practice

Volumn 19, Issue 2, 2013, Pages 313-326

  Fleseriu, Maria ^a   Molitch, Mark E ^b   Gross, Coleman E ^c   Schteingart, David ^d   Brooks Vaughan, T ^e   Biller, Beverly M K ^f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Corcept Therapeutics ^*  (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DEXAMETHASONE; EPLERENONE; ETOMIDATE; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MEVINOLIN; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PASIREOTIDE; SIMVASTATIN; SPIRONOLACTONE;

ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; BACKACHE; BLOOD PRESSURE REGULATION; CANCER RADIOTHERAPY; CANCER SURGERY; CONSTIPATION; CUSHING SYNDROME; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECTOPIC CORTICOTROPIN PRODUCTION; ENDOMETRIAL DISEASE; ENDOMETRIAL THICKNESS; FATIGUE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; GYNECOMASTIA; HEADACHE; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPERTENSION; HYPOGONADISM; HYPOKALEMIA; HYPOTENSION; LIMB PAIN; LIVER FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PAIN; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SOMNOLENCE; THYROID FUNCTION TEST; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VALVULAR HEART DISEASE; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; WELLBEING; XEROSTOMIA;

CUSHING SYNDROME; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; RECEPTORS, GLUCOCORTICOID;

EID: 84877101909     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12149.RA     Document Type: Review

References (76)

1. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593-5602.
2. Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary. 2004;7:253-256.
3. Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010;92(suppl 1):86-90.
4. Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord. 2010;10:10.
5. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab. 2002; 87:3662-3666.
6. Mancini T, Doga M, Mazziotti G, Giustina A. Cushing's syndrome and bone. Pituitary. 2004;7:249-252.
7. Valassi E, Biller BM, Klibanski A, Misra M. Adipokines and cardiovascular risk in Cushing's syndrome. Neuroendocrinology. 2012;95:187-206.
8. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96:632-642.
9. De Leo M, Pivonello R, Auriemma RS, et al. Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology. 2010;92(suppl 1):50-54.
10. Pivonello R, De Martino MC, De Leo M, et al. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol. 2007;51:1381-1391.
11. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93: 2454-2462.
12. Barahona MJ, Sucunza N, Resmini E, et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab. 2009;94:3365-3371.
13. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84:2664-2672.
14. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab. 1997;82:912-919.
15. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK. Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab. 2006;91:447-453.
16. Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology. 2010;92(suppl 1):65-70.
17. Sonino N, Fallo F, Fava GA. Psychosomatic aspects of Cushing's syndrome. Rev Endocr Metab Disord. 2010;11: 95-104.
18. Starkman MN, Giordani B, Berent S, Schork MA, Schteingart DE. Elevated cortisol levels in Cushing's disease are associated with cognitive decrements. Psychosom Med. 2001;63:985-993.
19. Alwani RA, de Herder WW, van Aken MO, et al. Biochemical predictors of outcome of pituitary surgery for Cushing's disease. Neuroendocrinology. 2010;91:169-178.
20. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63:549-559.
21. Fleseriu M, Loriaux DL, Ludlam WH. Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful. Curr Opin Endocrinol Diabetes Obes. 2007; 14:323-328.
22. Patil CG, Prevedello DM, Lad SP, et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008;93:358-362.
23. Pereira AM, van Aken MO, van Dulken H, et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab. 2003;88:5858-5864.
24. Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary. 2012;15:71-83.
25. Blevins LS Jr., Christy JH, Khajavi M, Tindall GT. Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab. 1998;83:63-67.
26. Esposito F, Dusick JR, Cohan P, et al. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 2006;91:7-13.
27. Hofmann BM, Hlavac M, Kreutzer J, Grabenbauer G, Fahlbusch R. Surgical treatment of recurrent Cushing's disease. Neurosurgery. 2006;58:1108-1118.
28. Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER Jr. Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery. 2008;63:266-270.
29. Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011;7:279-289.
30. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab. 2005;90: 4955-4962.
31. Baudry C, Coste J, Bou Khalil R, et al. Efficacy and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol. 2012;167:473-481.
32. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009; 94:115-122.
33. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol. 2008;158:91-99.
34. Chou SC, Lin JD. Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease. Endocr J. 2000;47:401-406.
35. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366:914-924.
36. Donadille B, Groussin L, Waintrop C, et al. Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center. J Clin Endocrinol Metab. 2010;95:537-544.
37. Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab. 1998;83:3542-3544.
38. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-2049.
39. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163:709-716.
40. Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N Engl J Med. 1979;300:459-464.
41. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94:223-230.
42. Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med. 1980;92:613-619.
43. van der Hoek J, Lamberts SW, Hofland LJ. The role of somatostatin analogs in Cushing's disease. Pituitary. 2004; 7:257-264.
44. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35:169-178.
45. von Werder K, Muller OA, Stalla GK. Somatostatin analogs in ectopic corticotropin production. Metabolism. 1996;45(suppl 1):129-131.
46. Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61: 536-540.
47. Bourgeois S, Pfahl M, Baulieu EE. DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU-486. EMBO J. 1984;3:751-755.
48. Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, Lähteenmäki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem. 1987;26:279-284.
49. Corecept Therapeutics Incorporated. Korlym™ (mifepristone) 300-mg tablets. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 202107s000lbl.pdf. Accessed May 30, 2012.
50. Basina M, Liu H, Hoffman AR, Feldman D. Successful long-term treatment of Cushing disease with mifepristone (RU486). Endocr Pract. 2012;18:e114-e120.
51. Beaufrère B, de Parscau L, Chatelain P, Morel Y, Aguercif M, François R. RU 486 administration in a child with Cushing's syndrome. Lancet. 1987;2:217.
52. Bilgin YM, van der Wiel HE, Fischer HR, De Herder WW. Treatment of severe psychosis due to ectopic Cushing's syndrome. J Endocrinol Invest. 2007;30:776-779.
53. Cassier PA, Abou-Amara-Olivieri S, Artru P, Lapalus MG, Riou JP, Lombard-Bohas C. Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases. Eur J Endocrinol. 2008;158:935-938.
54. Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009;160:1003-1010.
55. Chrousos G, Laue L, Nieman L, Udelsman R, Kawai S, Loriaux L. Clinical applications of RU 486, a prototype glucocorticoid and progestin antagonist. In: Mantero F, Scoggins B, Takeda R, Biglieri E, Funder J, eds. The Adrenal Hypertension: From Cloning to Clinic. New York, NY: Raven Press; 1989: 273-284.
56. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab. 2001;86:3568-3573.
57. Contreras P, Caviedas R, Rojas R, Lopez M. Adrenal cancer: tumor regression with ketoconazole or mifepristone (RU 486): in vivo and in vitro evidence supporting tumoral hormone dependency. The Endocrine Society 69th Annual Meeting, June 10-12, 1987; Indianapolis, IN. Abstract.
58. de Bruin C, Hofland LJ, Nieman LK, et al. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab. 2012;97:455-462.
59. Donckier JE, Michel LA, Berbinschi A, et al. Late recurrence of operated adrenocortical carcinoma: atrial natriuretic factor before and after treatment with mitotane. Surgery. 1989;105:690-692.
60. Dunnigan E, Carranza LB, McPhaul M. Mifepristone (RU-486) in the treatment of refractory Cushing's disease. The Endocrine Society Annual Meeting (ENDO 2010), June 19-22, 2010; San Diego, CA. Abstract P2-326.
61. Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf). 2001;54:399-404.
62. Nieman L, Udelsman R, Loriaux D, Chrousos G. Antiglucocorticoids: basic and clinical studies. In: D'Agata R, Chrousos G, eds. Recent Advances in Adrenal Regulation and Function. New York, NY: Raven Press; 1987: 235-258.
63. Oosterhuis JK, van den Berg G, Monteban-Kooistra WE, et al. Life-threatening Pneumocystis jiroveci pneumonia following treatment of severe Cushing's syndrome. Neth J Med. 2007;65:215-217.
64. van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med. 1991;114:143-144.
65. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591-598.
66. Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update. 2007;13:567-580.
67. Ioffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol. 2009;22: 450-459.
68. Taskinen MR, Nikkilä EA, Pelkonen R, Sane T. Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab. 1983;57:619-626.
69. Heikinheimo O, Ranta S, Grunberg S, Lähteenmäki P, Spitz IM. Alterations in the pituitary-thyroid and pituitary-adrenal axes-consequences of long-term mifepristone treatment. Metabolism. 1997;46:292-296.
70. Takiyama Y, Tanaka H, Takiyama Y, Makino I. The effects of hydrocortisone and RU486 (mifepristone) on iodide uptake in porcine thyroid cells in primary culture. Endocrinology. 1994;135:1972-1979.
71. Nelson DH, Meakin JW, Dealy JB Jr, Matson DD, Emerson K Jr, Thorn GW. ACTH-producing tumor of the pituitary gland. N Engl J Med. 1958;259:161-164.
72. Assié G, Bahurel H, Coste J, et al. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: a reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab. 2007;92:172-179.
73. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49: 509-533.
74. Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer. 1978;42:2177-2181.
75. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322:1195-1201.
76. Schteingart DE. Treating adrenal cancer. Endocrinologist. 1992;2:149-157.